Pyk2 is overexpressed in many cancers (43) and Pyk2 inhibition attenuated survival and proliferation of small cell lung cancer (66), breast cancer (80), ovarian clear cell cancer (85), multiple myeloma (88), and prostate cancer (31). This evidence concerns the gene PTK2B and ovarian clear cell cancer.